^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

STK11 expression

i
Other names: Serine/Threonine-Protein Kinase 11, Liver Kinase B1, Serine/Threonine-Protein Kinase LKB1, Polarization-Related Protein LKB1, STK11, Serine/Threonine Kinase 11, Serine/Threonine-Protein Kinase STK11, Renal Carcinoma Antigen NY-REN-19
Entrez ID:
Related biomarkers:
9d
Impact of LKB1 status on radiation outcome in patients with stage III non-small-cell lung cancer. (PubMed, Sci Rep)
LKB1 expression may serve as a potential biomarker for poor outcomes after receiving radiation in LA-NSCLC patients. Further studies to confirm the association and application are warranted.
Retrospective data • Journal
|
EGFR (Epidermal growth factor receptor) • STK11 (Serine/threonine kinase 11)
|
EGFR mutation • STK11 expression
2ms
Liver kinase B1 expression is associated with improved overall survival and decreased CD8+ tumor infiltrating lymphocytes in small cell lung cancer (ELCC 2024)
In this series, LKB1 expression was negatively associated with the presence of CD8+ TILs. Future studies will evaluate pts treated with chemoimmunotherapy and expand TIME analysis.
Clinical • Tumor-infiltrating lymphocyte • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • STK11 (Serine/threonine kinase 11) • CD8 (cluster of differentiation 8) • FOXP3 (Forkhead Box P3)
|
PD-L1 expression • STK11 expression • FOXP3 expression
|
PD-L1 IHC 22C3 pharmDx
3ms
STK11 (LKB1) mutation suppresses ferroptosis in lung adenocarcinoma by facilitating monounsaturated fatty acid synthesis. (PubMed, Open Med (Wars))
Subsequent rescue assays demonstrated that STK11 mutations hindered ferroptosis by impacting the synthesis of MUFAs in LUAD cells. This study provided evidence that STK11 mutations suppressed ferroptosis in LUAD cells by promoting MUFA synthesis, thus offering a novel research direction in the management of LUAD.
Journal
|
STK11 (Serine/threonine kinase 11) • SLC7A11 (Solute Carrier Family 7 Member 11) • SCD (Stearoyl-CoA Desaturase)
|
STK11 mutation • STK11 expression
4ms
Auraptene Enhances AMP-Activated Protein Kinase Phosphorylation and Thereby Inhibits the Proliferation, Migration and Expression of Androgen Receptors and Prostate-Specific Antigens in Prostate Cancer Cells. (PubMed, Int J Mol Sci)
Finally, in DU145 cells lacking the LKB1 gene, exogenously induced LKB1 expression restored AMPK phosphorylation by auraptene, indicating the essential role of LKB1. In summary, auraptene is a potent AMPK activator that acts by elevating the AMP/ATP ratio, thereby potentially suppressing prostate cancer progression, via at least three molecular mechanisms, including suppression of the mTOR-S6K pathway, reduced lipid synthesis, and AR downregulation caused by AMPK activation.
Journal
|
STK11 (Serine/threonine kinase 11) • AR (Androgen receptor)
|
AR expression • STK11 expression • AMPK expression
7ms
STK11 Mutation Status, Programmed Death Ligand Receptor-1 Expression, and Tumor Mutation Burden in Patients With Resected Brain Metastasis From Non-Small Cell Lung Cancer: Results of Multisite Study (CAP 2023)
Our analysis demonstrated significantly lower PD-L1 expression in NSCLC patients with BrMet and STK11m compared to STK11wt. STK11m demonstrated a poor correlation with PD-L1 and TMB. This association may impact response to therapy and prognosis in patients with STK11m.
Clinical • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker
|
EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • STK11 (Serine/threonine kinase 11)
|
PD-L1 expression • TP53 mutation • KRAS mutation • STK11 mutation • STK11 expression
8ms
Tumor-Derived Complement C3 as a Therapeutic Target in STK11 Mutant Non-Small Cell Lung Cancer (IASLC-WCLC 2023)
The complement pathway is a central part of the innate immune system and emerging data have identified local tumor induced complement pathway effector generation as distinct from peripheral complement components. Tumor produced complement factors can modulate tumor signaling and the TME promoting tumor growth and immune evasion. Our study implicates the complement pathway as a potential therapeutic target in STK11 mutant NSCLC with the growth of Stk11-KO tumors dependent on tumor-derived C3 suppressing T-cell immunity and these effects potentially mediated through the recruitment of PMN in the TME through the Cxcr2 signaling axis.
PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • STK11 (Serine/threonine kinase 11) • CD8 (cluster of differentiation 8) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • CXCR2 (Chemokine (C-X-C motif) receptor 2)
|
PD-L1 expression • KRAS mutation • STK11 mutation • STK11 expression
9ms
Alteration of STK11 Expression Associated With Cholangiocarcinoma Progression. (PubMed, In Vivo)
Alteration of STK11 mutational or mRNA/protein status might be used as a potential predictive biomarker for the prognosis of the clinical outcomes in CCA patients.
Journal
|
STK11 (Serine/threonine kinase 11)
|
STK11 mutation • STK11 expression
10ms
Clinicopathological and prognostic significance of LKB1 expression in gastric cancer: a systematic review and meta-analysis. (PubMed, Sci Rep)
In conclusion, LKB1 expression is related to tumor size, differentiation, depth of invasion, lymph node metastasis, and TNM stage, and low LKB1 expression can predict a poor prognosis. LKB1 is a potentially valuable prognosis signature and therapeutic target in GC patients.
Retrospective data • Review • Journal
|
STK11 (Serine/threonine kinase 11)
|
STK11 expression
10ms
LKB1 Positively Regulates Dendritic Cell-induced T Cell Immunity and Suppresses Tumor Development. (PubMed, Iran J Immunol)
Moreover, we found that the injection of the DCs with limited LKB1 expression before tumor inoculation could reduce their production of granzyme B (P<0.0001) and perforin (P=0.0042) from CD8+T cells, thereby impairing their cytotoxicity and promoting tumor growth. Our data suggest that LKB1 can enhance DC-mediated T cell immunity by restraining Treg development and thereby suppressing tumor growth.
Journal
|
STK11 (Serine/threonine kinase 11) • CD8 (cluster of differentiation 8) • IL10 (Interleukin 10) • GZMB (Granzyme B) • FOXP3 (Forkhead Box P3) • CD86 (CD86 Molecule)
|
STK11 expression • FOXP3 expression
10ms
CircDENND2D Inhibits PD-L1-Mediated Non-Small Cell Lung Cancer Metastasis and Immune Escape by Regulating miR-130b-3p/STK11 Axis. (PubMed, Biochem Genet)
STK11 knockdown or miR-130b-3p overexpression attenuated the function of circDENND2D overexpression on NSCLC cells. CircDENND2D inhibited metastasis and immune escape of NSCLC by regulating miR-130b-3p/STK11 axis.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • STK11 (Serine/threonine kinase 11) • CD8 (cluster of differentiation 8) • CDH1 (Cadherin 1) • CDH2 (Cadherin 2) • CDK7 (Cyclin Dependent Kinase 7)
|
CDH1 expression • STK11 expression
11ms
The liver kinase B1 supports mammary epithelial morphogenesis by inhibiting critical factors that mediate epithelial-mesenchymal transition. (PubMed, J Cell Physiol)
Thus, LKB1 sustains mammary epithelial morphogenesis by limiting pathways that promote EMT. The observed downregulation of LKB1 expression in breast cancer is therefore predicted to associate with enhanced EMT induced by SNAI1 and TGFβ family members.
Journal
|
STK11 (Serine/threonine kinase 11) • SNAI1 (Snail Family Transcriptional Repressor 1)
|
STK11 mutation • STK11 expression
12ms
Prognostic Value of Liver Kinase B1 (LKB1) in Gastric Cancer-Associated Tumor Microenvironment Immunity. (PubMed, Biomedicines)
Moreover, GC patients with low LKB1 expression had a poor objective response rate, and worse progression-free survival and overall survival when treated with pembrolizumab. In conclusion, LKB1 may be a potential immune checkpoint in GC patients.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • STK11 (Serine/threonine kinase 11) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • IFNG (Interferon, gamma) • CD28 (CD28 Molecule)
|
IFNG expression • STK11 expression
|
Keytruda (pembrolizumab)
1year
Gradual deterioration of fatty liver disease to liver cancer via inhibition of AMPK signaling pathways involved in energy-dependent disorders, cellular aging, and chronic inflammation. (PubMed, Front Oncol)
In addition, the expression of β-catenin, COX-2, and HMGB1 were upregulated, as well as the expression of p16 was downregulated. These findings suggest that changes in the AMPK signaling pathway exacerbate the deterioration of disrupted energy metabolism, chronic inflammation, hypoxia, and cellular aging in the tumor microenvironment, promoting the development of fatty liver into liver cancer.
Journal
|
STK11 (Serine/threonine kinase 11) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • HIF1A (Hypoxia inducible factor 1, alpha subunit) • HMGB1 (High Mobility Group Box 1)
|
HIF1A expression • STK11 expression
1year
LKB1 Loss Assessed by Immunohistochemistry as a Prognostic Marker to First-Line Therapy in Advanced Non-Small-Cell Lung Cancer. (PubMed, Curr Oncol)
(4) Patients with an LKB1 loss had worse clinical outcomes. This study warrants prospective assessments to confirm the prognostic role of the LKB1 expression in advanced NSCLC.
Journal • Metastases
|
EGFR (Epidermal growth factor receptor) • STK11 (Serine/threonine kinase 11)
|
EGFR wild-type • STK11 expression
over1year
STK11 mutation affects the killing effect of NK cells to promote the progression of lung adenocarcinoma. (PubMed, APMIS)
This study revealed the mechanism of STK11 mutation regulating NK cytotoxicity and promoting tumor development, providing scientific basis for the exploration of STK11-related LUAD therapeutic targets and theoretical reference for developing new NK cell-based immunotherapy.
Journal • IO biomarker
|
STK11 (Serine/threonine kinase 11) • IFNG (Interferon, gamma) • IL6 (Interleukin 6) • IL2 (Interleukin 2)
|
STK11 mutation • IFNG expression • STK11 deletion • STK11 expression • IL2 expression • IL6 expression
over1year
Lkb1 aggravates diffuse large B-cell lymphoma by promoting the function of Treg cells and immune escape. (PubMed, J Transl Med)
These findings confirmed that Lkb1-regulated Tregs are critical for immune escape in DLBCL, which emphasizes that Lkb1 is a potential target for the immunotherapy of DLBCL.
Journal • IO biomarker
|
STK11 (Serine/threonine kinase 11)
|
STK11 expression
2years
LKB1 down-modulation by miR-17 biologically and clinically mirrors LKB1-mutated NSCLC (AACR 2022)
We recently unveiled the vulnerability of KRAS/LKB1 co-mutated (KL) patient-derived xenografts (PDXs) to metabolic stress-based treatments, and a clinical trial to test the efficacy of metformin and fasting-mimicking diet on KL NSCLC is currently ongoing in our Institute... We validated miR-17 as epigenetic regulator of LKB1 expression in NSCLC tumors. We propose a miR-17 expression score potentially exploitable to discriminate LKB1WT NSCLC patients with impaired LKB1 expression and poor outcome, eligible for energy-stress-based treatments.
Clinical
|
KRAS (KRAS proto-oncogene GTPase) • STK11 (Serine/threonine kinase 11) • KL (Klotho) • MIR17 (MicroRNA 17)
|
KRAS mutation • STK11 expression • KRAS deletion
|
metformin
2years
LKB1 inhibits NFkB to suppress cancer stem cells in triple negative breast cancer (AACR 2022)
This results in reversal of EMT genes and diminished capabilities to form spheres. Future studies will be dedicated to identifying which of the 14 downstream kinases LKB1 activates to exert its functions.
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • STK11 (Serine/threonine kinase 11) • ITK (IL2 Inducible T Cell Kinase) • RELA (RELA Proto-Oncogene)
|
HER-2 amplification • ER expression • NFKB1 expression • STK11 expression
2years
LKB1 loss rewires JNK-induced apoptotic protein dynamics through NUAKs and sensitizes KRAS-mutant non-small cell lung cancers to combined KRAS G12C + MCL-1 blockade (AACR 2022)
We screened a panel of KRAS-mutant NSCLC cell lines as well as patient-derived xenograft (PDX) mouse models and observed that loss of the tumor suppressor STK11/LKB1 is associated with increased sensitivity to combined MAPK (either the KRAS G12C inhibitor sotorasib or MEK inhibitor trametinib) and MCL-1 inhibition (AMG 176). Consistent with this mechanism, ex vivo treatment of tumor tissue from a KRAS-LKB1 mutant NSCLC patient with sotorasib or trametinib increased MCL-1 dependent priming. These results reveal a novel link between LKB1 and the regulation of BCL-2 family proteins and provide preclinical rationale for evaluation of combined KRAS G12C + MCL-1 inhibitors for KRAS-LKB1 mutant NSCLC.
IO biomarker
|
KRAS (KRAS proto-oncogene GTPase) • BCL2 (B-cell CLL/lymphoma 2) • STK11 (Serine/threonine kinase 11) • MCL1 (Myeloid cell leukemia 1) • BCL2L1 (BCL2-like 1)
|
KRAS mutation • KRAS G12C • KRAS G12 • STK11 expression
|
Mekinist (trametinib) • Lumakras (sotorasib) • tapotoclax (AMG 176)
2years
The Natural Chemotherapeutic Capsaicin Activates AMPK through LKB1 Kinase and TRPV1 Receptors in Prostate Cancer Cells. (PubMed, Pharmaceutics)
Altogether, our results showed that capsaicin affected AMPK activity in an LKB1- and TRPV1-dependent fashion, linking TRPV1 with cell fate. These data also suggest that capsaicin may be a rational chemotherapeutic option for prostate tumors.
Journal
|
STK11 (Serine/threonine kinase 11)
|
STK11 expression • AMPK expression
2years
LKB1 expression and the prognosis of lung cancer: A meta-analysis. (PubMed, Medicine (Baltimore))
These results suggest that low expression of LKB1 can be considered as a unfavorable prognostic biomarker for human lung cancer, which should be further researched.
Retrospective data • Journal
|
STK11 (Serine/threonine kinase 11)
|
STK11 expression
over2years
No Tumor Suppressor Role for LKB1 in Prostate Cancer. (PubMed, DNA Cell Biol)
The LKB1 gene may be associated with benign transformations rather than the tumors in prostate pathogenesis when its expression and mutation status are considered. However, the mechanism of LKB1 in PCa needs further studies.
Journal
|
STK11 (Serine/threonine kinase 11)
|
STK11 expression
over2years
Clinical • Journal
|
STK11 (Serine/threonine kinase 11) • MIR17 (MicroRNA 17)
|
STK11 expression
over2years
The protein kinase LKB1 promotes self-renewal and blocks invasiveness in glioblastoma. (PubMed, J Cell Physiol)
Treatment with the clinically used drug metformin impaired 3D-gliomasphere formation and enhanced cytotoxicity induced by temozolomide, the primary chemotherapeutic drug against GBM. Our data support the parallel roles of LKB1 in maintaining mitochondrial homeostasis, 3D-gliomasphere survival, and hindering migration in GBM. Thus, the natural loss of, or pharmacological interference with LKB1 function, may be associated with benefits in patient survival but could result in tumor spread.
Journal
|
STK11 (Serine/threonine kinase 11) • SOX2 • NES (Nestin)
|
STK11 expression
|
temozolomide • metformin
almost3years
Protein Arginine Methyltransferase 5 Promotes Esophageal Squamous Cell Carcinoma Proliferation and Metastasis via LKB1/AMPK/mTOR Signaling Pathway. (PubMed, Front Bioeng Biotechnol)
Moreover, knocking down PRMT5 could weaken the tumor growth and lung metastasis in vivo with upregulating the LKB1 expression and the p-AMPK level and downregulating the p-mTOR expression. PRMT5 may act as a tumor-inducing agent in ESCC by modulating LKB1/AMPK/mTOR pathway signaling.
Journal
|
MMP2 (Matrix metallopeptidase 2) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • PRMT5 (Protein Arginine Methyltransferase 5) • CASP9 (Caspase 9) • MMP9 (Matrix metallopeptidase 9) • CDKN1A (Cyclin-dependent kinase inhibitor 1A)
|
BAX expression • STK11 expression • AMPK expression
almost3years
Suppression of m6A mRNA modification by DNA hypermethylated ALKBH5 aggravates the oncological behavior of KRAS mutation/LKB1 loss lung cancer. (PubMed, Cell Death Dis)
The above findings were confirmed in clinical KRAS-mutated lung cancer patients. We conclude that loss of LKB1 promotes ALKBH5 transcription by a DNA methylation mechanism, reduces m6A modification, and increases the stability of m6A target oncogenes, thus contributing to aggressive phenotypes of KRAS-mutated lung cancer.
Journal
|
KRAS (KRAS proto-oncogene GTPase) • SOX2 • KL (Klotho) • SMAD7 (SMAD Family Member 7) • ALKBH5 (AlkB Homolog 5, RNA Demethylase)
|
KRAS mutation • STK11 expression
almost3years
Serine/Threonine Kinase 11 Plays a Canonical Role in Malignant Progression of KRAS-mutant and GNAS-wild-type Intraductal Papillary Mucinous Neoplasms of the Pancreas. (PubMed, Ann Surg)
STK11 may play a canonical role in malignant progression and poor survival of patients with IPMNs. Aberrant STK11-driven phosphorylated AMPK downregulation may provide therapeutic opportunities with mTOR inhibitors/AMPK activators.
Journal
|
KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • TP53 (Tumor protein P53) • STK11 (Serine/threonine kinase 11) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • SMAD4 (SMAD family member 4) • GNAS (GNAS Complex Locus)
|
TP53 mutation • KRAS mutation • BRAF mutation • STK11 mutation • STK11 expression
almost3years
LKB1 down-modulation by miR-17 identifies NSCLC patients with worse prognosis eligible for energy-stress based treatments. (PubMed, J Thorac Oncol)
We identified miR-17 as a mediator of LKB1 expression in NSCLC tumors. This study proposes a miR-17 expression score potentially exploitable to discriminate LKB1 NSCLC patients with impaired LKB1 expression and poor outcome, eligible for energy-stress based treatments.
Clinical • Journal
|
KRAS (KRAS proto-oncogene GTPase) • MIR17 (MicroRNA 17)
|
KRAS mutation • STK11 expression • KRAS deletion
|
metformin
3years
[VIRTUAL] Liver kinase B1 (LKB1) and phosphorylated AMP kinase (AMPK) expression in small cell lung cancer (SCLC): Association with prognosis and tumour immune microenvironment (TIME) features (ELCC 2021)
No significant association was found between LKB1 and TIME; pAMPK was significantly associated with absent PD-L1 expression on TC (p = 0.040) and TIIC (p = 0.016).Conclusions LKB1/pAMPK deregulation may be associated with metastatic stage and lack of LKB1 expression warrants further validation as poor prognostic marker. Studies on a validation cohort of metastatic SCLC are ongoing while DNA genotyping of LKB1 is planned in LD
PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • STK11 (Serine/threonine kinase 11) • CD8 (cluster of differentiation 8) • FOXP3 (Forkhead Box P3) • AMPK (Protein Kinase AMP-Activated Catalytic Subunit Alpha 1)
|
PD-L1 expression • STK11 expression • AMPK expression
|
PD-L1 IHC 22C3 pharmDx
3years
[VIRTUAL] STK11 and Galectin-3 tissue expression entails a prognostic signature in immunotherapy treated NSCLC patients (ELCC 2021)
Moreover, STK11neg/Gal-3high signature had a relevant impact on CD4+, CD8+ and NK number and LDH levels.Conclusions STK11neg and Gal-3high may represent a poor prognostic trait in ICI-treated NSCLC patients. The correlation of STK11 and Galectin with circulating factors underlies a close interplay between tissue and peripheral blood compartments, ultimately featuring the tumor-host interaction and the proneness to respond to ICIs
Clinical • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • STK11 (Serine/threonine kinase 11) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • CD4 (CD4 Molecule)
|
KRAS mutation • STK11 mutation • STK11 expression • PD-L1-H
3years
STK11 loss drives rapid progression in a breast cancer patient resulting in pulmonary tumor thrombotic microangiopathy. (PubMed, Breast Cancer)
Transcriptome analysis showed a significant downregulation of proteins associated with apoptosis in the specimens with STK11 loss. STK11 loss may have triggered the rapid progression of PTTM from a comprehensive genomic analysis.
Clinical • Journal
|
TP53 (Tumor protein P53) • STK11 (Serine/threonine kinase 11)
|
TP53 mutation • STK11 mutation • STK11 expression • TP53 R213
over3years
Cigarette smoke-induced LKB1/AMPK pathway deficiency reduces EGFR TKI sensitivity in NSCLC. (PubMed, Oncogene)
Moreover, combined treatment of EGFR TKI with AMPK activators synergistically increases EGFR TKI sensitivity. Collectively, the current study suggests that LKB1 may serve as a marker to predict EGFR TKI sensitivity in smokers with NSCLC carrying EGFR and that the combination of EGFR TKI and AMPK activator may be a potentially effective therapeutic strategy against NSCLC with EGFR.
Journal
|
EGFR (Epidermal growth factor receptor) • STK11 (Serine/threonine kinase 11)
|
EGFR expression • STK11 expression
over3years
Clinical • Enrollment open
|
ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • STK11 (Serine/threonine kinase 11) • IGF1 (Insulin-like growth factor 1)
|
PD-L1 overexpression • ALK rearrangement • ROS1 rearrangement • STK11 expression
|
Keytruda (pembrolizumab) • cisplatin • carboplatin • pemetrexed • metformin
over3years
LKB1/STK11 Expression in Lung Adenocarcinoma and Associations with Patterns of Recurrence. (PubMed, Ann Thorac Surg)
Low LKB1/STK11 expression is associated with specific patient characteristics and poor postoperative prognosis in chemotherapy-naïve lung adenocarcinoma. Further investigation is warranted to delineate its clinical significance in the context of evaluating novel therapeutic agents in patients with resectable disease.
Journal
|
STK11 (Serine/threonine kinase 11) • CD8 (cluster of differentiation 8)
|
STK11 mutation • STK11 expression
over3years
Negative Regulation of Serine Threonine Kinase 11 (STK11) through miR-100 in Head and Neck Cancer. (PubMed, Genes (Basel))
This is, to our knowledge, the first report of miR-100-3p targeting STK11 in HNC. Together, these findings may support the importance of regulation of STK11 through post-transcriptional regulation in HNC and the possible contribution to the carcinogenesis process in this neoplasia.
Journal
|
STK11 (Serine/threonine kinase 11) • MIR106A (MicroRNA 106a)
|
STK11 mutation • STK11 expression
over3years
Association Between the Efficacy of Pembrolizumab and Low STK11/LKB1 Expression in High-PD-L1-expressing Non-small-cell Lung Cancer. (PubMed, In Vivo)
STK11/LKB1 expression, as measured by immunohistochemistry, could be a useful biomarker associated with the efficacy of pembrolizumab monotherapy for patients with NSCLC and a TPS ≥50%.
Clinical • Journal • PD(L)-1 Biomarker
|
PD-L1 (Programmed death ligand 1) • STK11 (Serine/threonine kinase 11)
|
PD-L1 expression • PD-L1 overexpression • STK11 mutation • STK11 expression
|
Keytruda (pembrolizumab)
over3years
Aldosterone from endometrial glands is benefit for human decidualization. (PubMed, Cell Death Dis)
Aldosterone biosynthesized in endometrial gland during mid-secretory phase promotes decidualization via activating MR/LKB1/p-AMPK/PDK4/p-CREB/FOXO1 signaling pathway. This study provides the valuable information for understanding the underlying mechanism during decidualization.
Journal
|
ATR (Ataxia telangiectasia and Rad3-related protein) • FOXO1 (Forkhead box O1)
|
STK11 expression
over3years
Association between LKB1 expression and prognosis of patients with solid tumours: an updated systematic review and meta-analysis. (PubMed, BMJ Open)
Low LKB1 expression predicts shorter OS, worse tumour differentiation, larger tumours, earlier lymph node metastasis and more advanced TNM stage. Low LKB1 expression may be a useful biomarker of poor clinicopathology and prognosis.
Retrospective data • Review • Journal
|
STK11 (Serine/threonine kinase 11)
|
STK11 expression
almost4years
[VIRTUAL] Modulating tumor immune microenvironment by the STK11/LKB1 signaling in breast cancer. (ASCO 2020)
Our findings suggest that suppression of STK11/LKB1 is correlated with early recurrence of breast cancer patients and contributes to modulate TIME. The STK11/LKB1 and downstream AMPK/mTORC1 pathways may be potential targets for immunotherapy. Research Funding: Taiwan goverment, National Cheng Kung University Hospital in Taiwan
IO biomarker
|
STK11 (Serine/threonine kinase 11) • CCL2 (Chemokine (C-C motif) ligand 2) • CXCL5 (Chemokine (C-X-C motif) ligand 5)
|
STK11 mutation • STK11 expression • CA9 expression